{
  "id": 9318911,
  "title": "Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?",
  "url": "https://urgent.news/2026/09/23/is-biocrysts-bcrx-newest-approval-bigger-than-it-looks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T10:26:22.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/biocryst-bcrx-newest-approval-bigger-102622733.html"
  },
  "original_language": "en",
  "account": "BioCryst Pharmaceuticals (BCRX) has announced that Japan's Ministry of Health, Labour and Welfare has approved its oral drug ORLADEYO for children aged 2 to 12 with hereditary angioedema/HAE. This marks the first and only oral prophylactic option for pediatric HAE patients in the country, creating a strong economic moat in one of the company's key international markets. The approval comes on the heels of US commercial shipments and pending applications in Europe and Canada, expanding ORLADEYO's global footprint to over 45 countries. BioCryst's revenue surged 34% year over year to $218.3 million in the second quarter, with GAAP operating profit at $98.5 million. The company's cash position stands at $354.0 million, with positive free cash flow even before licensing agreement proceeds. ORLADEYO's net revenue grew 1% year over year, with the increase driven by a $55.7 million European licensing deal for navenibart. The company is streamlining its R&D, ending internal discovery and closing its Birmingham site to prioritize external licensing. Retailer CareMed will be the sole specialty pharmacy partner for ORLADEYO starting in the third quarter. Institutional ownership has slightly decreased to 46 funds holding BCRX in the latest quarter, while short interest stands at 13.43% of the float. Trading at a forward P/E of 14.86, the equity remains priced defensively, with the market waiting for definitive proof of pediatric uptake and international pricing acceleration.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}